Fast Five Quiz: Test Your Knowledge of Systemic Treatment for Metastatic Breast Cancer

Winston W. Tan, MD

Disclosures

January 25, 2022

According to guidelines from the American Society of Clinical Oncology (ASCO), HER2-targeted therapy plus chemotherapy is the current approach for patients with HR-positive, HER2-positive breast cancer. In select cases, endocrine therapy plus either trastuzumab or lapatinib, or endocrine therapy alone, may be offered.

Although response rates are higher with chemotherapy than with hormone therapy, the incidence of potentially dangerous toxicity is also higher, and no evidence suggests that patients live longer as a result of receiving initial chemotherapy.

For additional information, refer to the ASCO guidelines.

Learn more about the treatment of metastatic breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....